SCHEMBL6178920

SCHEMBL6178920

Cc1nc(-c2ccccc2)cn1-c1ccc(CCO)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 1/20 0.41
SMN1; SMN2 Q16637 4/20 0.41
NPC1 O15118 4/20 0.41
RAB9A P51151 4/20 0.41
MAPT P10636 3/20 0.41
LMNA P02545 2/20 0.41
TDP1 Q9NUW8 2/20 0.41
ALDH1A1 P00352 3/20 0.40
KMT2A Q03164 2/20 0.40
MEN1 O00255 1/20 0.40
GAA P10253 1/20 0.40
HTT P42858 1/20 0.40
PTGS2 P35354 1/20 0.40
PTGS1 P23219 1/20 0.40
HSD11B1 P28845 2/20 0.40
SRC P12931 2/20 0.38
KDM4E B2RXH2 2/20 0.38
TP53 P04637 2/20 0.37
THRB P10828 1/20 0.37
PKM P14618 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6175631 0.87 PTGS1 (0.55) SMN1; SMN2NPC1RAB9AMAPTLMNA
SCHEMBL6179004 0.84 AGER (0.42) SMN1; SMN2NPC1RAB9AMAPTLMNA
SCHEMBL6173373 0.83 SMN1; SMN2 (0.43) GPR119SMN1; SMN2NPC1RAB9AMAPT
SCHEMBL6173956 0.83 CXCR3 (0.40) SMN1; SMN2NPC1RAB9AMAPTLMNA
SCHEMBL6175591 0.83 MAPT (0.39) GPR119SMN1; SMN2NPC1RAB9AMAPT
SCHEMBL14007394 0.82 SMN1; SMN2 (0.48) GPR119SMN1; SMN2NPC1RAB9AMAPT
SCHEMBL6173167 0.81 LMNA (0.39) SMN1; SMN2NPC1RAB9AMAPTLMNA
SCHEMBL6173846 0.81 AGER (0.54) SMN1; SMN2MAPTHSD11B1TP53
SCHEMBL6329632 0.80 TDP1 (0.38) SMN1; SMN2NPC1RAB9AMAPTLMNA
SCHEMBL6176741 0.78 GPR119 (0.41) GPR119SMN1; SMN2NPC1RAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6956050-B2 Imidazole compounds as anti-inflammatory and analgesic agents PFIZER, INC. (US) 2005-10-18 US disclosed
EP-1494667-A1 IMIDAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS Pfizer Japan Inc. (JP) 2005-01-12 EP disclosed
US-20030220372-A1 Imidazole compounds as anti-inflammatory and analgesic agents HIRANO MISATO (JP) 2003-11-27 US disclosed
WO-2003086390-A1 IMIDAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS PFIZER JAPAN INC. (JP) 2003-10-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030220372-A1 Imidazole compounds as anti-inflammatory and analgesic agents PTGS1, PTGS2, PTGES GPR119 1195/4885SMN1; SMN2 4565/4885NPC1 959/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.